Oregon Public Employees Retirement Fund Buys 354 Shares of AbbVie Inc. (NYSE:ABBV)

Oregon Public Employees Retirement Fund lifted its stake in shares of AbbVie Inc. (NYSE:ABBV) by 0.2% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 151,479 shares of the company’s stock after acquiring an additional 354 shares during the period. AbbVie makes up 0.5% of Oregon Public Employees Retirement Fund’s investment portfolio, making the stock its 26th biggest position. Oregon Public Employees Retirement Fund’s holdings in AbbVie were worth $26,918,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Checchi Capital Advisers LLC grew its position in AbbVie by 0.3% during the fourth quarter. Checchi Capital Advisers LLC now owns 23,353 shares of the company’s stock valued at $4,150,000 after acquiring an additional 61 shares during the last quarter. Bryn Mawr Capital Management LLC boosted its stake in shares of AbbVie by 4.5% in the 4th quarter. Bryn Mawr Capital Management LLC now owns 7,154 shares of the company’s stock valued at $1,271,000 after purchasing an additional 306 shares in the last quarter. Riverpoint Wealth Management Holdings LLC grew its holdings in shares of AbbVie by 0.9% during the 4th quarter. Riverpoint Wealth Management Holdings LLC now owns 8,256 shares of the company’s stock valued at $1,467,000 after purchasing an additional 75 shares during the last quarter. National Pension Service raised its position in AbbVie by 1.9% in the 4th quarter. National Pension Service now owns 3,416,539 shares of the company’s stock worth $607,119,000 after purchasing an additional 65,017 shares during the period. Finally, DMKC Advisory Services LLC bought a new stake in AbbVie in the fourth quarter worth $237,000. 70.23% of the stock is currently owned by hedge funds and other institutional investors.

AbbVie Trading Up 0.1 %

Shares of NYSE ABBV opened at $204.19 on Wednesday. The stock has a market cap of $360.46 billion, a P/E ratio of 85.08, a price-to-earnings-growth ratio of 1.62 and a beta of 0.58. The company has a debt-to-equity ratio of 17.94, a current ratio of 0.66 and a quick ratio of 0.55. AbbVie Inc. has a 1 year low of $153.58 and a 1 year high of $207.32. The firm has a 50-day moving average of $182.48 and a 200 day moving average of $186.61.

AbbVie (NYSE:ABBV) last issued its quarterly earnings results on Friday, January 31st. The company reported $2.16 EPS for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.82). AbbVie had a return on equity of 296.28% and a net margin of 7.59%. During the same period in the prior year, the firm earned $2.79 earnings per share. As a group, sell-side analysts expect that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, May 15th. Investors of record on Tuesday, April 15th will be paid a $1.64 dividend. This represents a $6.56 dividend on an annualized basis and a yield of 3.21%. The ex-dividend date of this dividend is Tuesday, April 15th. AbbVie’s payout ratio is 273.33%.

Wall Street Analyst Weigh In

Several research analysts have recently commented on the company. Raymond James reiterated an “outperform” rating and issued a $220.00 price objective (up previously from $218.00) on shares of AbbVie in a report on Monday, February 3rd. Daiwa America cut shares of AbbVie from a “strong-buy” rating to a “hold” rating in a report on Thursday, December 5th. Leerink Partnrs raised shares of AbbVie from a “hold” rating to a “strong-buy” rating in a research note on Friday, November 22nd. Wells Fargo & Company increased their price target on shares of AbbVie from $195.00 to $210.00 and gave the company an “overweight” rating in a research report on Monday, February 3rd. Finally, Piper Sandler upped their price objective on shares of AbbVie from $212.00 to $220.00 and gave the company an “overweight” rating in a research note on Tuesday, December 17th. Five equities research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $208.35.

Insider Activity at AbbVie

In other news, EVP Perry C. Siatis sold 5,778 shares of the business’s stock in a transaction on Thursday, February 20th. The stock was sold at an average price of $197.90, for a total value of $1,143,466.20. Following the completion of the transaction, the executive vice president now owns 22,381 shares in the company, valued at $4,429,199.90. The trade was a 20.52 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, SVP Kevin K. Buckbee sold 1,800 shares of the stock in a transaction on Monday, December 16th. The shares were sold at an average price of $172.24, for a total value of $310,032.00. Following the sale, the senior vice president now directly owns 6,983 shares in the company, valued at $1,202,751.92. This trade represents a 20.49 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.25% of the stock is currently owned by insiders.

AbbVie Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.